Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Shares Outstanding (2019 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Shares Outstanding for 7 consecutive years, with $57.7 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 1.02% to $57.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $57.7 million through Dec 2025, up 1.02% year-over-year, with the annual reading at $57.7 million for FY2025, 1.02% up from the prior year.
  • Shares Outstanding hit $57.7 million in Q4 2025 for Harmony Biosciences Holdings, roughly flat from $57.6 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $60.0 million in Q2 2023 to a low of $56.8 million in Q4 2023.
  • Historically, Shares Outstanding has averaged $58.1 million across 5 years, with a median of $57.7 million in 2025.
  • Biggest five-year swings in Shares Outstanding: skyrocketed 630.22% in 2021 and later dropped 5.28% in 2024.
  • Year by year, Shares Outstanding stood at $58.8 million in 2021, then rose by 1.34% to $59.6 million in 2022, then dropped by 4.77% to $56.8 million in 2023, then rose by 0.66% to $57.1 million in 2024, then rose by 1.02% to $57.7 million in 2025.
  • Business Quant data shows Shares Outstanding for HRMY at $57.7 million in Q4 2025, $57.6 million in Q3 2025, and $57.5 million in Q2 2025.